Leukaemias into the 21st century: Part 1: The acute leukaemias

Internal Medicine Journal

Volumn 42, Issue 11, 2012, Pages 1179-1186

  Brown, C M S ^a   Larsen, S R ^a   Iland, H J ^a   Joshua, D E ^a   Gibson, J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Acute leukaemia; ALL; AML; Leukaemia; Therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE SEVERITY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; LEUKEMIA; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; OPPORTUNISTIC INFECTIONS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869824539     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02938.x     Document Type: Article

References (41)

1. Tracey E, Kerr T, Dobrovic A, Currow D. Cancer in NSW: Incidence and Mortality Report 2008. Sydney: Cancer Institute NSW; 2010.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H etal. WHO classification of tumours of haematopoietic and lymphoid tissue: the international agency for research on cancer 2008.
3. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001; 8: 189-191.
4. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF etal., eds. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD. Available from URL:http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
6. Cancer in Australia: an overview. Australian Institute of Health and Welfare and Australian Associated Cancer Registry. 2010.
7. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK etal. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
8. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH etal. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
9. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L etal. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
10. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J etal. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
11. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A etal. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-5710.
12. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M etal. All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120: 1570-1580.
13. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E etal. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
14. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
15. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E etal. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
16. Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K etal. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 2012; 97: 227-234.
17. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R etal. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27-32.
18. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D etal. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
19. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T etal. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
20. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P etal. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
21. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM etal. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
22. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A etal. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-1248.
23. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R etal. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
24. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish acute leukemia registry. Clin Lymphoma Myeloma Leuk 2011; 11 (Suppl 1): S54-59.
25. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U etal. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
26. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J etal. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
27. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012; 26: 2176-2185.
28. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
29. Faderl S, O'Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D etal. Adult acute lymphoblastic leukemia. Cancer 2010; 116: 1165-1176.
30. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F etal. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466.
31. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S etal. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413.
32. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R etal. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116: 2070-2077.
33. Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J etal. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116-1123.
34. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S etal. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
35. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C etal. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002; 94: 773-779.
36. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park) 2011; 25: 328-335.
37. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T etal. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780.
38. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18: 2032-2035.
39. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F etal. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676-3678.
40. Horwitz ME. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 2011; 23: 197-202.
41. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK etal. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.